ProStrakan Group Says FDA Seeks More Data on Pain Ointment

April 1, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Reuters -- Scottish speciality pharmaceutical firm ProStrakan Group Plc (PSK.L) said U.S. health regulators sought further data on Rectogesic, an ointment for pain associated with chronic anal fissures, delaying approval for the drug.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

Food and Drug Administration (FDA)